These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16443257)

  • 1. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Schmidt-Lucke C; Paar WD; Stellbrink C; Nixdorff U; Hofmann T; Meurer J; Grewe R; Daniel WG; Hanrath P; Mügge A; Klein HU; Schmidt-Lucke JA
    Thromb Res; 2007; 119(1):27-34. PubMed ID: 16443257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Card Electrophysiol Rev; 2003 Dec; 7(4):382-6. PubMed ID: 15071260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
    Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once atrial fibrillation, always oral anticoagulation?
    Verheugt FW
    Thromb Res; 2007; 119(3):275-6. PubMed ID: 16426666
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
    Elliott DJ; Zhao L; Jasper SE; Lieber EA; Klein AL; Weintraub WS
    Am Heart J; 2008 Aug; 156(2):374.e1-6. PubMed ID: 18657673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
    Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
    Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study.
    Klein AL; Jasper SE; Katz WE; Malouf JF; Pape LA; Stoddard MF; Apperson-Hansen C; Lieber EA;
    Eur Heart J; 2006 Dec; 27(23):2858-65. PubMed ID: 17098762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new therapeutic strategy for electrical cardioversion of atrial fibrillation.
    de Luca I; Sorino M; Del Salvatore B; de Luca L
    Ital Heart J; 2001 Nov; 2(11):831-40. PubMed ID: 11770868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation in patients with atrial fibrillation].
    Mügge A
    Herz; 1996 Feb; 21(1):28-36. PubMed ID: 8647577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term fate of left atrial thrombi and incidence of cerebral embolism under continuous anticoagulation therapy].
    Strach K; Meyer C; Hackenbroch M; Tiemann K; Haase J; Pizulli L; Omran H; Schild H; Sommer T
    Rofo; 2005 Dec; 177(12):1706-12. PubMed ID: 16333795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
    Stellbrink C; Hanrath P; Nixdorff U; Hofmann T; Lehmacher W; Kühle K; Fetsch T; Grewe R; Schmidt-Lucke JA;
    Z Kardiol; 2002 Mar; 91(3):249-54. PubMed ID: 12001541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
    Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment.
    Audebert HJ; Schenk B; Tietz V; Schenkel J; Heuschmann PU
    Cerebrovasc Dis; 2008; 26(2):171-7. PubMed ID: 18628615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
    Schimpf T; Stellbrink C
    Med Klin (Munich); 2003 Feb; 98(2):91-5. PubMed ID: 12601533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anticoagulation in pregnancy and post partum in heat valve diseases, thrombosis or atrial fibrillation: fetal risk versus maternal thromboembolism].
    Gohlke-Bärwolf C
    Z Kardiol; 2001; 90 Suppl 4():49-56. PubMed ID: 11373944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation: ACUTE trial update.
    Asher CR; Klein AL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):387-91. PubMed ID: 15071261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.